Saiao Biotechnology

Saiao Biotechnology is a Shanghai-based Chinese cell therapy company focused on stem cell and immune cell therapeutics, with integrated R&D, cell preparation, storage, and translational medicine capabilities. The company’s lead asset is an amniotic epithelial stem cell product, iCELL hAESCs, which received an IND in China for steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation and has entered Phase 1/2 development. Saiao also reports a broader pipeline spanning regenerative medicine, autoimmune disease, neurodegeneration, viral infections, and oncology-related settings, including adipose-derived stem cell, antiviral cell therapy, and NK-cell programs. Beyond therapeutics, it operates multiple cGMP-standard cell preparation centers and tissue banks across China and has built internal digital manufacturing and traceability systems for cell production and transport. The company collaborates extensively with hospitals and academic institutions and positions itself as a platform-oriented developer of original Chinese cell therapy products.